Technology ID
TAB-2666

Novel Targets to Prevent Borrelia burgdorferi Infection and Lyme Disease

E-Numbers
E-573-2013-0
Lead Inventor
Gilmore, Robert (CDC)
Applications
Vaccines­­­
Therapeutics
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
  • Early-stage
  • In vitro data available
  • In vivo data available (animal)
Lead IC
CDC
ICs
CDC
B. burgdorferi-infected ticks can cause Lyme disease in mammalian hosts. This technology relates to the use of B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease vaccine candidates. In vivo animal studies demonstrate these outer surface proteins inhibit tick-to-host B. burgdorferi transmission. Presently, there is no vaccine approved for Lyme disease.
Commercial Applications
  • B. burgdorferi/Lyme disease vaccine development
  • B. burgdorferi diagnostics
  • Prevention of B. burgdorferi infection by passive immunity
  • Zoonotic/tick-borne disease surveillance
  • Public health vaccination programs against Lyme disease
Competitive Advantages
  • Currently no approved Lyme disease vaccines

Request More Info

Licensing Contact:
Specialist (ALS), Admin. Licensing
nihott@nih.gov

Patents

  • US
    Provisional (PRV) 61/814,741
    Filed on 2013-04-22

Publications

Collaborations

  • Licensing
Date Published